ALNYAlnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) sells RNAi therapeutics, a class of drugs that target genetic diseases at the molecular level. The company’s next catalyst is Nov 5, 2026 — Q3 2026 Earnings Release, which will test the business’s ability to sustain revenue growth and deliver on its clinical and commercial momentum.
- Alnylam’s revenue grew 65.2% YoY to $3.91B in 2026, with net income of $555.29M and free cash flow of $524.78M in the trailing twelve months.
- The company’s debt-to-equity ratio is 0.86x, and its net margin is 14.2%, reflecting strong pricing power and operational efficiency.
- Alnylam’s share price has historically reacted sharply to earnings and clinical data, with a recent bull trajectory anchored at $219.20 and a bear floor at $208.24 ahead of the Q3 2026 report.
The schedule
- Thu29Oct
- Tue9Feb
- Thu6May
- Thu5Aug
Past
- Sat25Jul
Actual outcome: Bull · $293.45 at outcome
Stock rose 8.0% from event to outcome date, aligning with the bull trajectory.
Stock rose 8.0% from event to outcome date, aligning with the bull trajectory.
- Wed3Jun
Actual outcome: Bull · $312.78 at outcome
Stock rose 6.9% from event to outcome date, aligning with the bull trajectory.
Stock rose 6.9% from event to outcome date, aligning with the bull trajectory.
- Tue12May
Actual outcome: Mixed · $294.30 at outcome
Alnylam presented new data analyses from the HELIOS-B Phase 3 study of vutrisiran in ATTR-CM, demonstrating robust clinical benefits across patient populations. Furthermore, management reaffirmed confidence in their TTR revenue guidance, citing access and prescriber growth. Despite these positive clinical and business updates, the stock reaction was muted, rising just 0.8% by the outcome date.
Alnylam presented new data analyses from the HELIOS-B Phase 3 study of vutrisiran in ATTR-CM, demonstrating robust clinical benefits across patient populations. Furthermore, management reaffirmed confidence in their TTR revenue guidance, citing access and prescriber growth. Despite these positive clinical and business updates, the stock reaction was muted, rising just 0.8% by the outcome date.
- Thu30Apr
Actual outcome: Bear · $295.91 at outcome
Alnylam reported a Q1 2026 earnings beat with EPS of $1.99 and a 187% surge in Amvuttra sales. Despite the strong top- and bottom-line results, the stock fell 4.4% as the company merely maintained its full-year TTR revenue guidance amid noted insurance and pricing headwinds, and the anticipated FDA regulatory milestone update was absent from the announcements.
Alnylam reported a Q1 2026 earnings beat with EPS of $1.99 and a 187% surge in Amvuttra sales. Despite the strong top- and bottom-line results, the stock fell 4.4% as the company merely maintained its full-year TTR revenue guidance amid noted insurance and pricing headwinds, and the anticipated FDA regulatory milestone update was absent from the announcements.
- Thu30Apr
Actual outcome: Bear · $297.45 at outcome
Price reached or fell below bear floor ($290.00) at outcome date.
Price reached or fell below bear floor ($290.00) at outcome date.
